APP and Alzheimer disease: The administration of transient iAβ depletion therapy and the following reset of the iAβ baseline would result in inactivation of the AβPP-independent iAβ production pathway, and would allow the ever decreasing number of viable AD-affected neurons to recover and restore their functionality.